268 related articles for article (PubMed ID: 25999738)
1. Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen.
Lacin S; Esin E; Karakas Y; Yalcin S
Onco Targets Ther; 2015; 8():1039-42. PubMed ID: 25999738
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature.
Kapur S; Xiao H; Zakowski MF; Hameed MR; Levin MB
World J Oncol; 2014 Apr; 5(2):81-89. PubMed ID: 29147383
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib for the treatment of metastatic medullary thyroid carcinoma.
Nix NM; Braun K
J Adv Pract Oncol; 2014 Jan; 5(1):47-50. PubMed ID: 25032033
[No Abstract] [Full Text] [Related]
4. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
Belum VR; Serna-Tamayo C; Wu S; Lacouture ME
Clin Exp Dermatol; 2016 Jan; 41(1):8-15. PubMed ID: 26009777
[TBL] [Abstract][Full Text] [Related]
5. Activating MET kinase rearrangements in melanoma and Spitz tumours.
Yeh I; Botton T; Talevich E; Shain AH; Sparatta AJ; de la Fouchardiere A; Mully TW; North JP; Garrido MC; Gagnon A; Vemula SS; McCalmont TH; LeBoit PE; Bastian BC
Nat Commun; 2015 May; 6():7174. PubMed ID: 26013381
[TBL] [Abstract][Full Text] [Related]
6. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.
Kwilas AR; Donahue RN; Tsang KY; Hodge JW
Cancer Cell Microenviron; 2015; 2(1):. PubMed ID: 26005708
[TBL] [Abstract][Full Text] [Related]
7. Igf-I influences everolimus activity in medullary thyroid carcinoma.
Gentilin E; Di Pasquale C; Rossi M; Tagliati F; Gagliano T; Rossi R; Pelizzo M; Merante Boschin I; Degli Uberti EC; Zatelli MC
Front Endocrinol (Lausanne); 2015; 6():63. PubMed ID: 25999915
[TBL] [Abstract][Full Text] [Related]
8. A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation.
Liu Y; Luan L; Wang X
Onco Targets Ther; 2015; 8():1061-8. PubMed ID: 25999741
[TBL] [Abstract][Full Text] [Related]
9. Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects.
Kreissl MC; Fassnacht M; Mueller SP
Nuklearmedizin; 2015; 54(3):88-93. PubMed ID: 26105716
[TBL] [Abstract][Full Text] [Related]
10. Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.
Grassadonia A; Caporale M; Tinari N; Zilli M; DeTursi M; Gamucci T; Vici P; Natoli C
J Cancer; 2015; 6(6):575-82. PubMed ID: 26000050
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies.
Wu B; Melara R; Rasmussen E; Zhou L; Wong T; Kitahara C; Ma M; Lu J; Gamelin E; Pickett CA; Sun YN
Cancer Chemother Pharmacol; 2015 Aug; 76(2):243-50. PubMed ID: 26032239
[TBL] [Abstract][Full Text] [Related]
12. Mesenteric ischemia after capecitabine treatment in rectal cancer and resultant short bowel syndrome is not an absolute contraindication for radical oncological treatment.
Perpar A; Brecelj E; Kozjek NR; Anderluh F; Oblak I; Vidmar MS; Velenik V
Radiol Oncol; 2015 Jun; 49(2):181-4. PubMed ID: 26029030
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Peters KB; Lou E; Desjardins A; Reardon DA; Lipp ES; Miller E; Herndon JE; McSherry F; Friedman HS; Vredenburgh JJ
Oncologist; 2015 Jul; 20(7):727-8. PubMed ID: 26025933
[TBL] [Abstract][Full Text] [Related]
14. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Taphoorn MJ; Henriksson R; Bottomley A; Cloughesy T; Wick W; Mason WP; Saran F; Nishikawa R; Hilton M; Theodore-Oklota C; Ravelo A; Chinot OL
J Clin Oncol; 2015 Jul; 33(19):2166-75. PubMed ID: 26014298
[TBL] [Abstract][Full Text] [Related]
15. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
16. Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells.
Li Y; Li Y; Liu Q; Wang A
Onco Targets Ther; 2015; 8():1043-51. PubMed ID: 25999739
[TBL] [Abstract][Full Text] [Related]
17. An isolated myeloid blast crisis presenting as optic nerve sarcoma in a patient with chronic myeloid leukaemia treated with imatinib.
Yamamoto H; Yamamoto M; Omoto E; Kato T; Tajima K
Br J Haematol; 2015 Aug; 170(3):290. PubMed ID: 26032918
[No Abstract] [Full Text] [Related]
18. Assessment of acute oxaliplatin-induced cold allodynia: a pilot study.
Ventzel L; Madsen CS; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
Acta Neurol Scand; 2016 Feb; 133(2):152-155. PubMed ID: 26032776
[TBL] [Abstract][Full Text] [Related]
19. PI3K mutations in breast cancer: prognostic and therapeutic implications.
Mukohara T
Breast Cancer (Dove Med Press); 2015; 7():111-23. PubMed ID: 26028978
[TBL] [Abstract][Full Text] [Related]
20. HER2/neu-directed therapy for biliary tract cancer.
Javle M; Churi C; Kang HC; Shroff R; Janku F; Surapaneni R; Zuo M; Barrera C; Alshamsi H; Krishnan S; Mishra L; Wolff RA; Kaseb AO; Thomas MB; Siegel AB
J Hematol Oncol; 2015 May; 8():58. PubMed ID: 26022204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
